Expression of CD33 is a predictive factor for effect of Gemtuzumab Ozogamicin at different doses in adult acute myeloid leukemia

It remains unclear in adult acute myeloid leukemia (AML) whether leukemic expression of CD33, the target antigen for Gemtuzumab Ozogamicin (GO), add prognostic information on GO effectiveness at different doses. CD33 expression quantified in 1583 patients recruited to UK-NCRI-AML17 (younger adults)...

Descripción completa

Detalles Bibliográficos
Autores principales: Khan, Naeem, Hills, Robert K, Virgo, Paul, Couzens, Stephen, Clark, Nithiya, Gilkes, Amanda, Richardson, Peter, Knapper, Steven, Grimwade, David, Russell, Nigel H, Burnett, Alan K, Freeman, Sylvie D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5419583/
https://www.ncbi.nlm.nih.gov/pubmed/27795558
http://dx.doi.org/10.1038/leu.2016.309

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5419583/
https://www.ncbi.nlm.nih.gov/pubmed/27795558
http://dx.doi.org/10.1038/leu.2016.309

Ejemplares similares